Amneal Ramping Up Malaria Drug Production to Treat Coronavirus Patients

Amneal Pharmaceuticals (NYSE: AMRX) announced on Friday that it would be ramping up production of its malaria drug, hydroxychloroquine sulfate, for potential use in treating COVID-19 patient symptoms. The company estimates that it will be able to manufacture around 20 million tablets of the drug in a month's time.